½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1553431

°¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)

Home Sleep Apnea Test Market Size, Share & Trends Analysis Report By Region (North America, Asia Pacific, Europe, Latin America, Middle East & Africa), And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠ¸®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024-2030³â CAGR 6.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 33¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç(HSAT)ÀÇ ±â¼úÀû Áøº¸¸¦ ¸ñÇ¥·Î ÇÏ´Â À¯¸í ±â¾÷ÀÇ ÅõÀÚ Áõ°¡°¡ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 3¿ù Belun Technology Company Ltd.´Â Belun Ring Ç÷§ÆûÀÇ Æò°¡¸¦ À§ÇÑ ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù. ¿þ¾î·¯ºí ±â¼úÀÎ Belun RingÀº ÀΰøÁö´É(AI)À» »ç¿ëÇÏ¿© ÀÇ·á Àü¹®°¡°¡ Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ(OSA)À» Áø´ÜÇÏ°í ¼ö¸é ´Ü°è¸¦ ºÐ·ùÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖ´Â ¿þ¾î·¯ºí ±â¼úÀÔ´Ï´Ù. Áý¿¡¼­ÀÇ ¼ö¸é Æò°¡´Â °ËÁö ¼Õ°¡¶ô ±ÙÀ§ºÎ¿¡ Âø¿ëÇÏ´Â ÀÌ ¸µÇü Àåºñ¿¡ ÆÞ½º¿Á½Ã¹ÌÅÍ¿Í °¡¼Óµµ°è°¡ ³»ÀåµÇ¾î ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¼ö¸é¹«È£ÈíÁõ À¯º´·ü Áõ°¡¿Í ¼ö¸é¹«È£ÈíÁõ Ä¡·á¸¦ À§ÇÑ ±â¼úÀûÀ¸·Î Áøº¸µÈ ¼Ö·ç¼ÇÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ ±¸»óÀÇ È®´ëµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù.2024³â 5¿ù National Council on Aging, Inc.°¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é ¾à 6¹é¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¼ö¸é¹«È£ÈíÁõÀ¸·Î °ø½Ä Áø´ÜÀ» ¹Þ¾ÒÀ¸¸ç, ¹Ì±¹³» 3,000¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼ö¸é¹«È£ÈíÁõ À¯º´·üÀº ³ªÀÌ°¡ µé¼ö·Ï Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ¿¬±¸¿¡ µû¸£¸é 65¼¼ ÀÌ»óÀÇ ¼ºÀÎÀº Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ ¹ßº´ À§ÇèÀÌ 56% ´õ ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

COVID-19´Â ÃÖÁ¾»ç¿ëÀÚµéÀÌ ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀ» äÅÃÇϵµ·Ï À¯µµÇÏ¿© ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, 2021³â 3¿ù Itamar MedicalÀÌ Sleep Medicine Publication°ú ÇÔ²² ½Ç½ÃÇÑ ¼³¹®Á¶»ç¿¡ µû¸£¸é ¼ö¸é Ŭ¸®´ÐÀÇ 29%°¡ °¡Á¤³» ¼Ö·ç¼Çº¸´Ù ½ÇÇè½Ç °Ë»ç¸¦ ¼±È£ÇÏ°í ÀÖÀ¸¸ç, ÀÌ ºñÀ²Àº ´õ ³·¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ¹Ý¼ÛÀ̳ª ±â±â °Ë¿ªÀÌ ÇÊ¿ä ¾ø´Â ÀÏȸ¿ë °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç(HSAT)ÀÇ µµÀÔ¿¡ ÈûÀÔÀº ¹Ù Å®´Ï´Ù. Áï°¢ÀûÀÎ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Â °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»çÀÇ Çâ»óµÈ ±â´ÉÀº Ãʱ⠼±º°°Ë»çºÎÅÍ Áø´Ü, Ä¡·á±îÁö ȯÀÚÀÇ °æ°ú¸¦ ÀüÅëÀûÀÎ °Ë»ç½Ç °Ë»ç¿¡ ÀÇÁ¸ÇÏ´Â °æÇâÀ» ´õ¿í ¾àÈ­½ÃÄ×½À´Ï´Ù. COVID-19 ±â°£ Áß 67%ÀÇ Å¬¸®´ÐÀÌ ½ÇÇè½Ç ȯÀÚ °Ë»ç°¡ Áߵ¿¡¼­ Å©°Ô °¨¼ÒÇß´Ù°í º¸°íÇÑ ¹Ý¸é, 66%´Â °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ÀÌ¿ëÀÌ ºñ½ÁÇÑ ¼öÁØÀ¸·Î Áõ°¡Çß´Ù°í ´äÇßÀ¸¸ç, 65%ÀÇ Å¬¸®´ÐÀº COVID-19 ÀÌÈÄ¿¡µµ ÀÌ·¯ÇÑ Ãß¼¼°¡ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óÇÏ°í ¼ö¸é¹«È£ÈíÁõ ÁõÈıºÀÇ ÁÖ¿ä Áø´Ü ¼ö¸é¹«È£ÈíÁõ Áø´ÜÀÇ ÁÖ¿ä ¼ö´ÜÀ¸·Î HSAT¸¦ ¼±È£ÇÏ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ÃÖÁ¾»ç¿ëÀÚÀÇ ÁøÈ­ÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ÀμöÇÕº´, ÆÄÆ®³Ê½Ê, Á¦ÈÞ, »ç¾÷ È®Àå, ½ÅÁ¦Ç° Ãâ½Ã µî ´Ù¾çÇÑ Àü·«À» äÅÃÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 3¿ù ¿µ±¹¿¡ º»»ç¸¦ µÐ ÀÇ·á ±â¼ú ±â¾÷ AcurableÀº ÃÖ±Ù FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Æ ¹Ì±¹¿¡¼­ Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ Áø´Ü¿ë AcuPebble Àåºñ¸¦ Ãâ½ÃÇÏ¿© ½ÃÀå ¹üÀ§¸¦ È®´ëÇß½À´Ï´Ù. ¿ø°Ý ¼ö¸é¹«È£Èí °Ë»ç ±â´ÉÀ» °­È­ÇÏ¿© ½Å¼ÓÇÑ Áø´Ü, Ä¡·á ÃËÁø ¹× »óÅ °ü¸® °³¼±À» ÃËÁøÇÕ´Ï´Ù.

°¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀå º¸°í¼­ - ÁÖ¿ä ³»¿ë

  • 2023³â ½ÃÀå Á¡À¯À²Àº ºÏ¹Ì°¡ 47.74%·Î °¡Àå Å®´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â È£Èí±â Áúȯ ¹ßº´·ü Áõ°¡, Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ(OSA)¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Á¤ºÎ Áö¿ø Á¤Ã¥ÀÌ ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº 2024-2030³â ¿¬Æò±Õ 8.0%ÀÇ °¡Àå ºü¸¥ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÌ Áö¿ª¿¡¼­ ±â¼úÀûÀ¸·Î Áøº¸µÈ HSATÀÇ Ã¤ÅÃÀÌ Å©°Ô Áõ°¡ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • ÁÖ¿ä ±â¾÷Àº ¼­ºñ½º Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÏ°í Áö¿ªÀû ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ Á¦Ç° Ãâ½Ã, Á¦ÈÞ, Àμö, ÇÕº´ µî ´Ù¾çÇÑ Àü·«À» äÅÃÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå³» Ä¡¿­ÇÑ °æÀïÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
  • °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå °¡Á¤¿ë ¼ö¸é¹«È£Èí °Ë»ç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®, Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ½º³À¼ô
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦5Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷/°æÀïÀÇ ºÐ·ù
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À²/Æ÷Áö¼Ç ºÐ¼®, 2023³â
  • ±â¾÷ °³¿ä
    • Resmed
    • Itamar Medical Ltd a subsidiary of ZOLL Medical Corporation(a ASAHI KASEI company)
    • Cleveland Medical Devices Inc.
    • Compumedics Limited
    • Onera Technologies BV
    • Sunrise
    • Nox Medical
    • Watermark Medical
    • Bittium
    • Cadwell Industries Inc.
KSA 24.09.25

Home Sleep Apnea Test Market Growth & Trends:

The global home sleep apnea test market size is expected to reach USD 3.38 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing investment by prominent players, aimed at technological advancements in the home sleep apnea tests (HSAT). For instance, in March 2024, Belun Technology Company Ltd. launched a clinical trial aimed at the evaluation of the Belun Ring platform. The Belun Ring, a wearable technology, employs Artificial Intelligence (AI) to assist medical professionals in diagnosing Obstructive Sleep Apnea (OSA) and categorizing sleep phases. For home sleep assessments, individuals use this ring device, which incorporates a pulse oximeter and an accelerometer and is worn on the proximal index finger.

Moreover, the increasing prevalence of sleep apnea coupled with growing initiatives aimed at increasing awareness regarding the availability of technologically advanced solutions to treat sleep apnea is also contributing to the market growth. According to data published by the National Council on Aging, Inc. in May 2024 showcases that approximately 6 million Americans are formally diagnosed with sleep apnea; however, the condition is estimated to impact 30 million people within the U.S. The prevalence of sleep apnea tends to increase with age, the studies indicate that adults aged 65 and above exhibit a 56% higher risk of developing obstructive sleep apnea.

COVID-19 positively impacted the market as it forced the end users to adopt remote medical solutions. According to a survey conducted by Itamar Medical in partnership with Sleep Medicine Publication in March 2021 showcased that 29% of sleep clinics prioritize in-lab studies over at-home solutions-a proportion anticipated to decline further. This shift is supported by the adoption of disposable Home Sleep Apnea Tests (HSATs), which prevent the need for return shipping or equipment quarantine. Enhanced capabilities of home-based apnea tests, delivering instant results, further reduce the dependency on traditional in-lab studies for patient progression from initial screening through to diagnosis and treatment. During the pandemic, 67% of the clinics reported a moderate to significant reduction in in-lab patient studies, whereas 66% noted a comparable increase in the utilization of home sleep apnea tests. A substantial 65% of clinics foresee the continuation of this trend post-COVID, with a preference for HSATs as the primary diagnostic tool for sleep apnea.

Furthermore, key players in the market are adopting various strategies such as mergers & acquisitions, partnerships, collaborations, expansions, and new product launches to cater to the evolving demand of end users and strengthen their market positions. For instance, in March 2023, UK-based medical technology firm Acurable expanded its market reach by launching the AcuPebble device for the diagnosis of obstructive sleep apnea in the U.S. following recent FDA approval. Initially introduced in Europe in 2021, this device enhances the capability for remote, home-based sleep apnea testing, facilitating prompt diagnosis, accelerated treatment, and improved management of the condition.

Home Sleep Apnea Test Market Report Highlights:

  • North America held the largest market share of 47.74% in 2023. The market growth is attributed to a rising incidence of respiratory conditions, enhanced recognition of Obstructive Sleep Apnea (OSA), and supportive government policies that are fueling the market growth.
  • The market in Asia Pacific is expected to register the fastest growth rate at a CAGR of 8.0% from 2024 to 2030. The growth is attributed to the significant adoption of technologically advanced HSATs in the region.
  • Major players are employing various strategies such as product launches, collaborations, acquisitions, and mergers to expand their service portfolios and enhance their geographical presence, leading to significant competition within the market.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional scope
    • 1.1.2. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Home Sleep Apnea Test Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market Opportunity Analysis
  • 3.2. Home Sleep Apnea Test Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis

Chapter 4. Home Sleep Apnea Test Market: Regional Estimates & Trend Analysis, By Product, By Application, By End Use

  • 4.1. Regional Market Share Analysis, 2023 & 2030
  • 4.2. Regional Market Dashboard
  • 4.3. Global Regional Market Snapshot
  • 4.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 4.5. North America
    • 4.5.1. U.S.
      • 4.5.1.1. Key country dynamics
      • 4.5.1.2. Regulatory framework/ reimbursement structure
      • 4.5.1.3. Competitive scenario
      • 4.5.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.5.2. Canada
      • 4.5.2.1. Key country dynamics
      • 4.5.2.2. Regulatory framework/ reimbursement structure
      • 4.5.2.3. Competitive scenario
      • 4.5.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.5.3. Mexico
      • 4.5.3.1. Key country dynamics
      • 4.5.3.2. Regulatory framework/ reimbursement structure
      • 4.5.3.3. Competitive scenario
      • 4.5.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Billion)
  • 4.6. Europe
    • 4.6.1. UK
      • 4.6.1.1. Key country dynamics
      • 4.6.1.2. Regulatory framework/ reimbursement structure
      • 4.6.1.3. Competitive scenario
      • 4.6.1.4. UK market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.2. Germany
      • 4.6.2.1. Key country dynamics
      • 4.6.2.2. Regulatory framework/ reimbursement structure
      • 4.6.2.3. Competitive scenario
      • 4.6.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.3. France
      • 4.6.3.1. Key country dynamics
      • 4.6.3.2. Regulatory framework/ reimbursement structure
      • 4.6.3.3. Competitive scenario
      • 4.6.3.4. France market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.4. Italy
      • 4.6.4.1. Key country dynamics
      • 4.6.4.2. Regulatory framework/ reimbursement structure
      • 4.6.4.3. Competitive scenario
      • 4.6.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.5. Spain
      • 4.6.5.1. Key country dynamics
      • 4.6.5.2. Regulatory framework/ reimbursement structure
      • 4.6.5.3. Competitive scenario
      • 4.6.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.6. Norway
      • 4.6.6.1. Key country dynamics
      • 4.6.6.2. Regulatory framework/ reimbursement structure
      • 4.6.6.3. Competitive scenario
      • 4.6.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.7. Sweden
      • 4.6.7.1. Key country dynamics
      • 4.6.7.2. Regulatory framework/ reimbursement structure
      • 4.6.7.3. Competitive scenario
      • 4.6.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.6.8. Denmark
      • 4.6.8.1. Key country dynamics
      • 4.6.8.2. Regulatory framework/ reimbursement structure
      • 4.6.8.3. Competitive scenario
      • 4.6.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Billion)
  • 4.7. Asia Pacific
    • 4.7.1. Japan
      • 4.7.1.1. Key country dynamics
      • 4.7.1.2. Regulatory framework/ reimbursement structure
      • 4.7.1.3. Competitive scenario
      • 4.7.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.7.2. China
      • 4.7.2.1. Key country dynamics
      • 4.7.2.2. Regulatory framework/ reimbursement structure
      • 4.7.2.3. Competitive scenario
      • 4.7.2.4. China market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.7.3. India
      • 4.7.3.1. Key country dynamics
      • 4.7.3.2. Regulatory framework/ reimbursement structure
      • 4.7.3.3. Competitive scenario
      • 4.7.3.4. India market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.7.4. Australia
      • 4.7.4.1. Key country dynamics
      • 4.7.4.2. Regulatory framework/ reimbursement structure
      • 4.7.4.3. Competitive scenario
      • 4.7.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.7.5. South Korea
      • 4.7.5.1. Key country dynamics
      • 4.7.5.2. Regulatory framework/ reimbursement structure
      • 4.7.5.3. Competitive scenario
      • 4.7.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.7.6. Thailand
      • 4.7.6.1. Key country dynamics
      • 4.7.6.2. Regulatory framework/ reimbursement structure
      • 4.7.6.3. Competitive scenario
      • 4.7.6.4. Singapore market estimates and forecasts 2018 to 2030, (USD Billion)
  • 4.8. Latin America
    • 4.8.1. Brazil
      • 4.8.1.1. Key country dynamics
      • 4.8.1.2. Regulatory framework/ reimbursement structure
      • 4.8.1.3. Competitive scenario
      • 4.8.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.8.2. Argentina
      • 4.8.2.1. Key country dynamics
      • 4.8.2.2. Regulatory framework/ reimbursement structure
      • 4.8.2.3. Competitive scenario
      • 4.8.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Billion)
  • 4.9. MEA
    • 4.9.1. South Africa
      • 4.9.1.1. Key country dynamics
      • 4.9.1.2. Regulatory framework/ reimbursement structure
      • 4.9.1.3. Competitive scenario
      • 4.9.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.9.2. Saudi Arabia
      • 4.9.2.1. Key country dynamics
      • 4.9.2.2. Regulatory framework/ reimbursement structure
      • 4.9.2.3. Competitive scenario
      • 4.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.9.3. UAE
      • 4.9.3.1. Key country dynamics
      • 4.9.3.2. Regulatory framework/ reimbursement structure
      • 4.9.3.3. Competitive scenario
      • 4.9.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Billion)
    • 4.9.4. Kuwait
      • 4.9.4.1. Key country dynamics
      • 4.9.4.2. Regulatory framework/ reimbursement structure
      • 4.9.4.3. Competitive scenario
      • 4.9.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Billion)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Key company market share/position analysis, 2023
  • 5.4. Company Profiles
    • 5.4.1. Resmed
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Itamar Medical Ltd a subsidiary of ZOLL Medical Corporation ( a ASAHI KASEI company)
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Cleveland Medical Devices Inc.
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Compumedics Limited
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Onera Technologies B.V.
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Sunrise
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Nox Medical
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Watermark Medical
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Bittium
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Cadwell Industries Inc.
      • 5.4.10.1. Company overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦